Insulin Pen Injectors: Technical Requirements and Market Trends

Introduction: The Evolution of Insulin Delivery

Insulin pen injectors have fundamentally transformed diabetes management since their introduction. Replacing traditional vial-and-syringe methods, these pen-shaped devices offer patients a convenient, discreet, and precise way to administer insulin. Today, insulin pens are the preferred choice for millions of diabetes patients worldwide, serving as an essential tool in the daily management of both Type 1 and Type 2 diabetes.

The global insulin pen market reflects this widespread adoption. Valued at approximately $9.6 billion in 2024, the market is expected to grow from $10.6 billion in 2025 to $25.6 billion by 2034, at a compound annual growth rate of 10.3%. This remarkable growth is driven by rising diabetes prevalence, technological advancements, and increasing awareness of diabetes self-management.

For pharmaceutical packaging manufacturers like Vialab Pharmaceutical Packaging Co., Ltd. , understanding the technical requirements and market trends of insulin pen injectors is essential. As a specialized provider of drug delivery and packaging components—including injection pens (disposable and reusable), glass vials and tubes, sterile vials, and aluminum caps—Vialab is positioned at the intersection of precision engineering and patient-centric design.

This article explores the technical standards governing insulin pen injectors, the materials and design considerations that ensure safety and efficacy, and the market trends shaping the future of insulin delivery.

Part I: Technical Requirements for Insulin Pen Injectors

The Regulatory Framework: ISO 11608 Standards

Insulin pen injectors are classified as medical devices and must meet rigorous international standards to ensure safety, efficacy, and reliability. The cornerstone of these requirements is the ISO 11608 series, which provides a comprehensive technical framework for needle-based injection systems.

The ISO 11608 standard family originated in the 1990s in response to the urgent need for dose accuracy in insulin therapy. Over the years, it has evolved significantly—from a “design prescriptive” approach that specified dimensions and materials, to a “performance-oriented” framework that focuses on what the system must achieve. This shift emphasizes the validation of final system performance rather than merely prescribing how components should be built.

The ISO 11608 series now extends to seven parts, covering:

Part 1: Needle-based injection systems—general requirements and test methods
Part 2: Needles—requirements and test methods
Part 3: Containers and interfaces—requirements and test methods
Part 4: Electronic and electromechanical features
Part 5: Automated functions
Part 6: Visual accessibility
Part 7: On-body delivery systems (OBDS)

The 2022 revision of ISO 11608-1 introduced the concept of “primary functions”—those that, if not performed to specification, would directly result in failure to accurately deliver the drug and/or cause unacceptable harm to the patient. Dose accuracy is unequivocally the core of these primary functions.

Dose Accuracy: The Critical Performance Parameter

Dose accuracy is the most critical performance parameter for any insulin pen injector. Patients depend on these devices to deliver precise insulin doses—often down to 0.5 to 1 unit increments—to maintain blood glucose control. Even small deviations can have serious clinical consequences.

ISO 11608-1:2012 specifies accuracy requirements across three dosage levels: 1 unit, 40 units, and 80 units, allowing a deviation of no more than ±1 unit at the lowest dosage level. The 2022 version adopts a more scientifically rigorous approach to design verification, shifting from the earlier recommendation of “15 devices, 4 samples per dose setting” to “one sample recorded from each of 60 devices”—better reflecting device-to-device and within-device variability.

Key performance metrics defined by the standard include:

Deliverable volume: The actual volume that can be expelled from the container when operated according to instructions.

Dose accuracy: The difference between the intended dose and the actual delivered dose, with specific allowable deviations for different dose ranges.

Piston sliding performance: Including starting force, sustained thrust, and rebound force. The uniformity of silicone oil coating directly determines the stability of sliding resistance, which significantly impacts dose accuracy. Testing must be conducted under controlled temperature and humidity conditions using media that simulate the rheological properties of the drug.

Residual volume: Particularly for self-destructing syringes, the standard strictly requires that when the plunger is pushed with light pressure (e.g., 5N) after self-destruction, liquid leakage must not exceed extremely low limits (e.g., 0.01 mL).

Mechanical and Functional Testing

Beyond dose accuracy, insulin pens must undergo comprehensive mechanical and functional testing. According to ISO 11608-1, ISO 11608-2, and ISO 11608-3, these tests measure thrust force, metering accuracy, piston movement, and other critical parameters. The testing systems must ensure reproducibility of results while minimizing operator influence.

Testing protocols typically include:

Dose setting and delivery force measurement: Ensuring the device can be comfortably operated by patients with varying hand strength
Drop testing: Verifying mechanical reliability under accidental drops
Button life testing: Confirming durability over the device’s intended lifespan
Container closure integrity: Ensuring the seal between the cartridge and the needle interface remains intact

The US Pharmacopeia also references ISO 11608 standards in chapters USP <1382> and USP <382>, which provide information and requirements for evaluating the functional suitability of elastomeric components as part of injectable drug packaging/delivery systems.

Materials and Container Compatibility

Insulin pen injectors consist of multiple components, each with specific material requirements:

Cartridges (Penfill): Typically made of Type I borosilicate glass due to its excellent barrier properties, low extractables profile, and compatibility with high-concentration protein formulations such as U200/U300 insulin. Standard 3 mL cartridges conform to ISO 11608-3, with an internal diameter of 9.7 mm.

Elastomeric components: Rubber stoppers and seals must maintain container closure integrity while allowing smooth piston movement. Fluoropolymer-coated elastomers are increasingly used to minimize extractables and leachables.

Pen body: Disposable pens are typically made from engineering plastics, while reusable pens incorporate metal components for durability. Materials must be biocompatible, durable, and capable of maintaining dimensional tolerances across the device’s lifespan.

Needles: Must conform to ISO 11608-2 standards and are available in various gauges and lengths to accommodate different patient needs and injection sites.

For pharmaceutical packaging manufacturers, ensuring compatibility between the drug formulation and the container closure system is paramount. This requires comprehensive extractables and leachables (E&L) studies, as well as stability testing under various temperature and humidity conditions.

Disposable vs. Reusable Insulin Pens

Insulin pens fall into two primary categories:

Disposable (pre-filled) pens: These come pre-filled with insulin and are discarded after the cartridge is empty. They offer convenience and eliminate the need for cartridge loading, making them popular among patients new to insulin therapy.

Reusable pens: These accept replaceable insulin cartridges and can be used for several years. They are more cost-effective in the long run and often preferred by patients on long-term insulin therapy.

According to market data, reusable insulin pens captured the largest revenue share at 50.7% in 2025, accounting for 52.5% of overall sales. This preference reflects both economic considerations and the growing adoption of smart pen technologies, which are more commonly integrated into reusable devices.

Part II: Market Trends and Growth Drivers

Market Size and Growth Projections

The global insulin pen market is experiencing robust growth across multiple segments. Different research firms provide varying estimates, all pointing to strong expansion:

Global Market Insights estimates the market at $10.6 billion in 2025, projected to reach $25.6 billion by 2034 at a CAGR of 10.3%.
GII Research projects the market at $7.91 billion in 2025, reaching $13.64 billion by 2032 at a CAGR of 8.1%.
百谏方略 (DIResearch) forecasts 2025 market size at $7.567 billion, reaching $21.27 billion by 2032 at a CAGR of 15.91%.

The broader insulin pens, syringes, pumps, and injectors market grew from $23.52 billion in 2025 to an estimated $26.14 billion in 2026, at a CAGR of 11.1%.

Key Growth Drivers

Rising Diabetes Prevalence: According to the World Health Organization’s 2024 report, the number of people with diabetes increased from 200 million in 1990 to 830 million in 2022. In 2021, diabetes was the direct cause of 1.6 million deaths, with 47% occurring before age 70. This dramatic increase drives demand for convenient, effective insulin delivery systems.

Technological Advancements: Continuous innovation in pen design—including improved dose accuracy, ease of use, and portability—enhances patient experience and encourages wider adoption. Integration with digital health platforms is revolutionizing patient care.

Growing Awareness of Diabetes Self-Management: Enhanced education and awareness campaigns empower patients to take control of their condition, with more patients choosing insulin pens over traditional syringes for their simplicity and ease of use.

Global Health Initiatives: The WHO launched the Global Diabetes Compact to reduce diabetes risk and ensure equitable, comprehensive, affordable, and high-quality treatment for all diagnosed individuals. This includes five global coverage targets to be achieved by 2030.

Regional Market Dynamics

Europe is the largest insulin pen market, accounting for approximately 48% of global market share. The region benefits from strong healthcare infrastructure, high diabetes awareness, and a supportive regulatory environment.

Asia-Pacific follows closely, accounting for about 27% of the market. The region is experiencing the fastest growth, driven by rising diabetes rates, increasing healthcare expenditure, and growing adoption of advanced insulin delivery devices.

North America holds a significant market share with a high adoption rate of advanced insulin delivery devices. The U.S. insulin pen market alone is estimated at $2.1 billion in 2025.

China, as the world’s second-largest economy, is forecast to reach a projected market size of $2.7 billion by 2032, trailing a CAGR of 11.1%.

Competitive Landscape

The insulin pen market is highly concentrated, with a few major players dominating the landscape:

Novo Nordisk led with over 30% market share in 2024. The top three companies—Novo Nordisk, Eli Lilly, and Sanofi—occupied approximately 69% of the market. The top five players, including Ypsomed and Becton Dickinson, collectively held 54% of the market share in 2024.

Other notable players include Dongbao, Owen Mumford, and Ganlee. These companies compete through continuous innovation, strategic collaborations, and strong global distribution networks.

Part III: The Smart Insulin Pen Revolution

Connected Devices Reshaping Diabetes Care

Smart insulin pens represent the most significant technological advancement in insulin delivery since the introduction of the pen itself. These devices integrate digital health features—dose tracking, dose reminders, connectivity with mobile apps, and data sharing with healthcare providers—to enable more effective diabetes management.

The smart insulin pen market is accelerating rapidly. In 2025, the global smart insulin pen market reached approximately $153.1 million to $904.06 million, depending on the definition and scope. With nearly 60% of digitally active insulin users shifting to connected dosing tools, the market is projected to reach $349.4 million by 2035 at a CAGR of 8.6%. Other sources project the smart insulin pen market to grow from $994.47 million in 2026 to $2,454.72 million by 2034, at a CAGR of 11.96%.

Key features of smart insulin pens include:

Bluetooth connectivity: Over 50% of devices in major markets now feature Bluetooth connectivity for seamless data transmission to smartphone apps.

Dose tracking and reminders: Automated recording of injection details, including time, date, and dose delivered, with reminders to prevent missed doses.

Data integration: Sync with continuous glucose monitors (CGMs) to create a closed-loop “monitoring-medication-tracking” ecosystem. Over 45% of healthcare professionals prefer integrated smart pen solutions due to improved adherence and data accuracy.

Cartridge authentication: NFC or BLE-based authentication ensures patients are using genuine, non-expired insulin cartridges.

The Connected Ecosystem

The integration of smart insulin pens into broader digital health ecosystems is transforming diabetes management. For example, partnerships between device manufacturers and CGM providers enable real-time synchronization of glucose data and insulin injection records, allowing patients and healthcare providers to make data-driven treatment decisions.

Over 55% of new models now feature enhanced connectivity, while nearly 30% integrate algorithm-based dose optimization for better therapeutic outcomes. Reusable smart pens account for approximately 74% of the segment in some regions, reflecting patient preference for durable, connected devices.

Challenges and Opportunities

Despite rapid growth, the smart insulin pen market faces challenges:

Affordability: High costs limit access in price-sensitive markets and for uninsured patients.

Interoperability: Connectivity issues affect nearly 25% of connected device deployments in critical healthcare systems.

Regulatory complexity: Complex regulations and lengthy approval processes can delay market entry for innovative devices.

However, significant opportunities exist:

Cost-effective solutions for emerging markets through innovation in manufacturing and materials
AI and IoT integration for personalized diabetes management
Biosimilar insulin expansion reducing overall treatment costs
Growing homecare and outpatient channels now account for over a quarter of device placements in multiple regions

Conclusion: The Future of Insulin Pen Injectors

Insulin pen injectors have evolved from simple mechanical devices into sophisticated drug delivery systems that integrate precision engineering, advanced materials, and digital connectivity. The technical requirements defined by ISO 11608 standards ensure that these devices deliver accurate, reliable doses—a non-negotiable requirement for patient safety. Meanwhile, market trends point toward continued growth driven by rising diabetes prevalence, technological innovation, and the shift toward connected, data-driven diabetes management.

At Vialab Pharmaceutical Packaging Co., Ltd. , we recognize the critical role that high-quality components play in insulin pen injectors. From precision-engineered glass cartridges and sterile vials to aluminum caps and customized packaging solutions, every component must meet the exacting standards that diabetes patients deserve. Our advanced production lines, cleanroom facilities, and ISO/GMP-compliant quality systems ensure consistency, integrity, and compliance for global healthcare partners.

As the global insulin pen market continues its trajectory toward $25 billion and beyond, the demand for reliable, innovative packaging solutions will only intensify. The shift toward smart, connected devices presents new opportunities for packaging manufacturers to deliver components that support digital integration—from NFC-enabled labels to connectivity-ready cartridge designs.

The future of insulin delivery is precise, connected, and patient-centric. At Vialab, we are committed to delivering the safety, reliability, and innovation that this future demands.